Takeda said that it conducted the Phase III trial of Takepron for the treatment of Japanese patients who take low-dose aspirin in long period and submitted an application for an additional indication of prevention of onset of low-dose aspirin related gastric and duodenal ulcer based on the result of the trial.
Once this application is approved, Takeda expects to help patients taking aspirin with Takepron for prevention of onset of low-dose aspirin ulcer to allow extended use of low-dose aspirin.
Takepron is a proton pump inhibitor discovered by Takeda and has been launched since 1992 in Japan.